Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial

Azoulay, É.; Lemiale, V.; Mokart, D.; Nseir, S.; Argaud, L.; Pène, F.; Kontar, L.; Bruneel, F.; Klouche, K.; Barbier, F.; Reignier, J.; Berrahil-Meksen, Lilia; Louis, G.; Constantin, J.; Mayaux, J.; Wallet, F.; Kouatchet, A.; Peigne, V.; Théodose, I.; Pérez, P.; Girault, C.; Jaber, S.; Oziel, J.; Nyunga, M.; Terzi, N.; Bouadma, L.; Lebert, C.; Lautrette, A.; Bigé, N.; Raphalen, J.; Papazian, L.; Darmon, M.; Chevret, S.; Demoule, A.

doi:10.1001/jama.2018.14282

Public

Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial

Shared by NobleBlocks on Nov 27, 2018 • 12:00 AM UTC

Authors:

É. Azoulay

V. Lemiale

D. Mokart

Abstract

Importance High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF). Objective To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy. Design, Setting, and Participan...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!